BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Capricor Therapeutics

3 posts

Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company that is focused on the discovery, development, and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases.

Capricor’s innovative technology builds upon a large body of scientific research and enables them to approach the treatment of diseases in novel ways. The company is a leader in the field of exosome science.

Capricor’s lead candidate is CAP-1002. This “off-the-shelf” cardiac cell therapy is currently in clinical development for the treatment of Duchenne muscular dystrophy (DMD) and COVID-19.

CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications. They have been administered to approximately 200+ human subjects throughout multiple clinical trials.

Capricor studies have been showing that exosome technology is significantly active in several disease models. The company is developing its exosome technologies as a next generation platform in a variety of diseases.

BioTech CEO InterviewsPioneering Cell & Exosome Therapies for Rare Diseases | Capricor Therapeutics Interview with Dr. Linda Marbán and AJ Bergmann

  • BioTech Health X
  • August 10, 2024
Join us on BioTech Health X as we sit down with Dr. Linda Marbán, CEO, and AJ Bergmann,…
0 Shares
0
0
0
0
0
0
0
Capricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD)

Biotech NewsCapricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD)

  • BioTech Health X
  • September 3, 2021
Capricor Therapeutics Announces HOPE-2 Trial Data Presentation On September 2nd, Capricor Therapeutics (NASDAQ: CAPR) announced an upcoming company…
0 Shares
0
0
0
0
0
0
0
Capricor CEO to Present at American Society of Gene and Cell Therapy Annual Meeting Ahead of Q1 Earnings Update

Biotech NewsCapricor CEO to Present at American Society of Gene and Cell Therapy Annual Meeting Ahead of Q1 Earnings Update

  • BioTech Health X
  • May 12, 2021
May 13 is a busy day for biotechnology company Capricor Therapeutics (NASDAQ: CAPR). The company which focuses on…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Vigil Neuroscience (VIGL): The Tiny Biotech Sanofi Just Bet $600M On
  • Agios (AGIO) Could Explode in 2025—And It’s Not Just Hype
  • Hinge Health (HNGE) IPO’d Big—But It’s Just Getting Started
  • Warren Buffett Missed This One: Why Johnson & Johnson (JNJ) May Be the Best Buy He Never Made
  • Buy the Dip? Molina Healthcare (MOH) Just Hit a 52-Week Low—and the Upside Is Stunning
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • July 6, 2025
    Vigil Neuroscience (VIGL): The Tiny Biotech Sanofi Just Bet $600M On
    • July 6, 2025
    Agios (AGIO) Could Explode in 2025—And It’s Not Just Hype
    • July 6, 2025
    Hinge Health (HNGE) IPO’d Big—But It’s Just Getting Started
    • July 6, 2025
    Warren Buffett Missed This One: Why Johnson & Johnson (JNJ) May Be the Best Buy He Never Made
    • July 6, 2025
    Buy the Dip? Molina Healthcare (MOH) Just Hit a 52-Week Low—and the Upside Is Stunning
Recent Posts
  • Buy the Biotech Blue-Chip Before the Surge: Why Amgen (AMGN) Could Soar in 2025
    • July 6, 2025
  • Rigel Pharmaceuticals (RIGL) is Quietly Building a Biotech Empire
    • July 6, 2025
  • Wall Street’s Best-Kept Biotech Secret? Why Pharvaris (PHVS) Could Be the Next $3 Billion Breakout
    • July 4, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (1)
  • Biotech News (243)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top